Log in or Sign up for Free to view tailored content for your specialty!
Cirrhosis/Liver Failure News

‘No beneficial effects’ from simvastatin plus rifaximin for decompensated cirrhosis
The addition of simvastatin plus rifaximin to standard therapy did not improve outcomes among patients with decompensated cirrhosis who were at high risk for clinical complications, according to a study published in JAMA.
Q&A: ‘Unacceptable’ medical deserts leave rural patients with rare diseases stranded

Approximately 14% of the U.S. population lives in rural areas, where access to health care may be limited by insurance coverage, geography and infrastructure, and provider shortages, according to HHS.
Metabolic surgery slashed risk for adverse outcomes in MASH-related cirrhosis, obesity

Metabolic surgery significantly lowered risk for major adverse liver outcomes vs. nonsurgical management among patients with obesity and compensated cirrhosis from metabolic dysfunction-associated steatohepatitis, according to study data.
Log in or Sign up for Free to view tailored content for your specialty!
FMT safe, linked to reduced hepatic encephalopathy recurrence in patients with cirrhosis

Fecal microbiota transplant, regardless of dose or route, was safe and associated with reduced hepatic encephalopathy recurrence among patients with cirrhosis receiving lactulose and rifaximin, according to a study in Journal of Hepatology.
Hispanic patients with alcohol use disorder face greater odds for hepatitis, cirrhosis

Hispanic patients hospitalized for alcohol use disorder were more likely to develop alcohol-associated hepatitis, decompensated cirrhosis and related complications compared with non-Hispanic white patients, according to published data.
Alfapump implant gains FDA premarket approval for recurrent, refractory cirrhotic ascites

The FDA has granted premarket approval to Sequana Medical’s alfapump implantable device for the treatment of recurrent or refractory ascites due to cirrhosis, according to a company press release.
FDA fast tracks Lipocine’s oral androgen receptor agonist for sarcopenia in cirrhosis

The FDA granted fast track designation to Lipocine’s LPCN 1148, an oral androgen receptor agonist containing testosterone dodecanoate, for the treatment of sarcopenia in patients with decompensated cirrhosis, according to the manufacturer.
MELD 3.0 reduces sex-based disparities in liver transplant access, waitlist outcomes

SAN DIEGO — Waitlist mortality and liver transplant rates for women appear to more closely align with rates for men after the implementation of MELD 3.0, according to late-breaking data presented at The Liver Meeting.
HHS removes barriers for HIV-positive organ recipients

HHS adopted a final rule eliminating the requirement that patients with HIV in need of a kidney or liver transplant participate in a clinical study to receive an organ from a donor with HIV, according to an agency press release.
VIDEO: Combination tobevibart, elebsiran induces ‘rapid virologic suppression’ in HDV
SAN DIEGO — Combination tobevibart and elebsiran led to “profound and rapid virologic suppression” as well as normalization of alanine aminotransferase at week 24 in chronic hepatitis D virus infection, according to preliminary data.
-
Headline News
Societies take stand against off-brand GLP-1s over safety concerns
March 17, 202515 min read -
Headline News
THA stem design may have a larger impact on periprosthetic fracture risk vs. cement use
February 06, 20251 min read -
Headline News
Self-perceived stress linked to cryptogenic ischemic stroke in young women
March 14, 20253 min read
-
Headline News
Societies take stand against off-brand GLP-1s over safety concerns
March 17, 202515 min read -
Headline News
THA stem design may have a larger impact on periprosthetic fracture risk vs. cement use
February 06, 20251 min read -
Headline News
Self-perceived stress linked to cryptogenic ischemic stroke in young women
March 14, 20253 min read